%0 Journal Article %1 Morabito.2006 %A Morabito, A. %A De, Maio E. %A Di, Maio M. %A Normanno, N. %A Perrone, F. %D 2006 %J Oncologist. %K & A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use %N 7 %P 753-764 %T Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions %U PM:16880234 %V 11 %X Angiogenesis plays a central role in the process of tumor growth and metastatic dissemination. The vascular endothelial growth factor (VEGF) family of peptide growth factors and receptors are key regulators of this process. Agents directed either against VEGF or VEGF receptors (VEGFRs) have been developed. The tyrosine kinase inhibitors of VEGFRs are low-molecular-weight, ATP-mimetic proteins that bind to the ATP-binding catalytic site of the tyrosine kinase domain of VEG-FRs, resulting in blockade of intracellular signaling. Several of these agents are currently in different phases of clinical development. Large randomized phase III trials have demonstrated the efficacy of sunitinib and sorafenib in the treatment of patients affected by gastrointestinal stromal tumors and renal cancer refractory to standard therapies, respectively. Positive results also have been reported with the combination of ZD6474 and chemotherapy in previously treated non-small cell lung cancer patients. For oth

@article{Morabito.2006, abstract = {Angiogenesis plays a central role in the process of tumor growth and metastatic dissemination. The vascular endothelial growth factor (VEGF) family of peptide growth factors and receptors are key regulators of this process. Agents directed either against VEGF or VEGF receptors (VEGFRs) have been developed. The tyrosine kinase inhibitors of VEGFRs are low-molecular-weight, ATP-mimetic proteins that bind to the ATP-binding catalytic site of the tyrosine kinase domain of VEG-FRs, resulting in blockade of intracellular signaling. Several of these agents are currently in different phases of clinical development. Large randomized phase III trials have demonstrated the efficacy of sunitinib and sorafenib in the treatment of patients affected by gastrointestinal stromal tumors and renal cancer refractory to standard therapies, respectively. Positive results also have been reported with the combination of ZD6474 and chemotherapy in previously treated non-small cell lung cancer patients. For oth}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Morabito, A. and De, Maio E. and Di, Maio M. and Normanno, N. and Perrone, F.}, biburl = {https://www.bibsonomy.org/bibtex/2a983fe521c531b49f0265112de4eeb86/kanefendt}, interhash = {ebef4d4b3fe290e1b36eab6ddc855bd9}, intrahash = {a983fe521c531b49f0265112de4eeb86}, journal = {Oncologist.}, keywords = {& A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use}, number = 7, pages = {753-764}, timestamp = {2010-02-05T11:28:54.000+0100}, title = {Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions}, url = {PM:16880234}, volume = 11, year = 2006 }